<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698617</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-202</org_study_id>
    <nct_id>NCT03698617</nct_id>
  </id_info>
  <brief_title>A Phase IIa Study Investigating the Tolerance, Efficacy and Safety of HSK3486</brief_title>
  <official_title>A Phase IIa, Open-label, Propofol-controlled ,Dose-escalation, Multi-center Study to Evaluate the Tolerance, Efficacy and Safety of HSK3486 for Induction of General Anesthesia in Elective Surgery Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIa, open-label, propofol-controlled ,dose-escalation, multi-center Study to&#xD;
      evaluate the tolerance, efficacy and safety of HSK3486 for induction of general anesthesia in&#xD;
      elective surgery patients.This study is consisted of two cohorts, dose-escalation and&#xD;
      dose-expansion cohorts. The doses in dose- expansion cohort were selected from&#xD;
      dose-escalation results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2016</start_date>
  <completion_date type="Actual">July 18, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The success rate of induction of general anesthesia</measure>
    <time_frame>during induction of general anesthesia on day 1</time_frame>
    <description>To find the MTD or the RP2D of HSK3486 in the induction of general anesthesia, the success rate of induction of general anesthesia is the primary outcome measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from start of IMP administration to loss of eyelash reflex</measure>
    <time_frame>during induction of general anesthesia on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from start of IMP administration to loss of consciousness</measure>
    <time_frame>during induction of general anesthesia on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from start of IMP administration to intubation and the intubation reaction</measure>
    <time_frame>during induction of general anesthesia on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE) total scores(0-30) by time point</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
    <description>Change from baseline in Mini-Mental State Examination (MMSE) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in blood pressure （systolic, diastolic and mean arterial pressure)</measure>
    <time_frame>pre-dose to 20 minutes post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in heart rate</measure>
    <time_frame>pre-dose to 20 minutes post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in arterial oxygen saturation</measure>
    <time_frame>pre-dose to 20 minutes post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Induction of General Anaesthesia</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Cohort:&#xD;
0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.</description>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>For induction of general anesthesia</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Inpatients required tracheal intubation under general anesthesia and a non-emergency&#xD;
             non-cardiothoracic and non-extracranial elective surgery for an estimated duration of&#xD;
             ≤ 3 h ;.&#xD;
&#xD;
          2. Males or females, aged ≥ 18 and ≤ 65 years old;&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 19 and ≤ 30 kg/m2;&#xD;
&#xD;
          4. ASA grade I~II;&#xD;
&#xD;
          5. Capable of understanding the procedure and method of this study, willing to sign an&#xD;
             informed consent form and to complete this study in strict accordance with the study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients were contraindicated in general anesthesia.;&#xD;
&#xD;
          2. Patients with a known sensitivity to propofol, opioids, naloxone, eggs, soy products&#xD;
             or a medical condition such that these agents were contraindicated&#xD;
&#xD;
          3. Patients in receipt of any investigational drug within 30 days before screening.&#xD;
&#xD;
          4. Patients in receipt of propofol, opioid , other sedative or anesthetic or analgesics&#xD;
             within one month prior to the screening period.&#xD;
&#xD;
          5. Patients in receipt of general anesthesia surgery within two weeks prior to the&#xD;
             screening period.&#xD;
&#xD;
          6. The patient has some history or evidence of increased risk of sedation or anesthesia,&#xD;
             such as cardiovascular disease, respiratory disease, cerebrovascular disease, liver,&#xD;
             kidney, blood system, or metabolic system disease prior to the screening period.&#xD;
&#xD;
          7. Abnormal laboratory results consisting of any of the following: :&#xD;
&#xD;
        1) AST and ALT≥ 2×ULN； 2）TBIL≥ 1.5×ULN； 3）Hb≤ 90g/L; 4）ANC≤1.5×109/L; 5) PLT≤80×109/L； 6）&#xD;
        serum creatinine≥ 1.5×ULN.&#xD;
&#xD;
        8. Patients with a history of drug or ethanol abuse with the past 3 months. 9. Pregnant&#xD;
        women or female patients with a positive serum or urine human chorionic gonadotropin&#xD;
        pregnancy test at screening or baseline or lactating female patients. . 10. 10. Patients&#xD;
        with a positive Allen 's test who collected arterial blood for PK study.&#xD;
&#xD;
        11. Patients with respiratory management difficulties. 12. Patients with an inability to&#xD;
        communicate well with the investigator, or deemed unsuitable according to the investigator&#xD;
        (in each case providing a reason).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of WMU</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

